A Phase 1, Open-Label, Single-Dose, Three-Period, Randomized Study Comparing the Pharmacokinetics of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Healthy Adult Subjects

Trial Profile

A Phase 1, Open-Label, Single-Dose, Three-Period, Randomized Study Comparing the Pharmacokinetics of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Mercaptamine bitartrate (Primary) ; Omeprazole
  • Indications Nephropathic cystinosis
  • Focus Pharmacokinetics
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 16 Feb 2018 New trial record
    • 06 Feb 2018 Primary endpoint (Maximum observed concentration (Cmax)) has been met, according to results published in the Advances in Therapy Journal.
    • 06 Feb 2018 Primary endpoint (Area under the concentrationtime curve from time 0 extrapolated to infinity (AUC0-infinity)) has been met, according to results published in the Advances in Therapy Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top